Quanterix Releases Financial Results for the Third Quarter of 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Get Free Real-Time Notifications for Any Stock
Monitor tickers like QTRX with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on QTRX
Wall Street analysts forecast QTRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QTRX is 7.50 USD with a low forecast of 7.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
0 Buy
2 Hold
0 Sell
Hold
Current: 6.680
Low
7.00
Averages
7.50
High
8.00
Current: 6.680
Low
7.00
Averages
7.50
High
8.00
About QTRX
Quanterix Corporation is engaged in fueling scientific discovery through ultra-sensitive biomarker detection. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Quanterix Publishes Landmark Alzheimer’s Study with C-Index of 0.90
- Significant Findings: Quanterix's study published in JAMA Network Open demonstrates that a multi-biomarker model achieves a high C-index of 0.90 for clinical risk assessment, significantly enhancing the identification of early symptoms of Alzheimer’s disease.
- Cutting-Edge Technology: Utilizing ultra-sensitive Simoa® technology to measure four critical biological axes of Alzheimer’s, the research indicates that the combined use of multiple biomarkers provides a more comprehensive view of clinical risk, advancing early diagnosis of the disease.
- Innovative Product Leadership: The launch of LucentAD Complete, based on biomarkers evaluated in the study, aims to provide a comprehensive amyloid risk score for symptomatic individuals, marking Quanterix's leadership in Alzheimer’s diagnostics.
- Clinical Application Prospects: The study underscores the importance of identifying potential fast progressors, with Quanterix's multi-analyte approach offering new solutions for clinical trial enrollment and patient care, driving the evolution of personalized medicine.
Continue Reading
Rich Sparkle Holdings Signs $39 Million Share Offering Agreement
- Stock Surge: Rich Sparkle Holdings Ltd's shares skyrocketed 115% to $52.00 following the signing of a $39 million agreement for 3 million ordinary shares, indicating strong market confidence in its financing strategy.
- Positive Market Reaction: The offering price of $13 per share is significantly lower than the current market price, reflecting optimistic investor expectations regarding the company's growth potential, which may provide essential funding for future expansions.
- Significant Industry Impact: The successful financing of Rich Sparkle Holdings not only enhances its market position but could also attract more investor attention to the sector, potentially driving up stock prices of related companies.
- Optimistic Future Outlook: With the influx of capital, the company is poised to accelerate its business development and market expansion, further solidifying its competitive advantage in the industry.
Continue Reading